120 – Season 8 Recap & Future Outlook (S8E15)

All right, welcome back to the deep dive. We've
spent this entire season really digging into
the world of drug regulations and all the systems
for keeping an eye on medications after they're
already out there being used by patients. Yeah,
it's been a pretty deep dive for sure. And for
this deep dive, what we're going to do is kind
of like step back a bit and bring together all
the key things that we've learned, especially
in season eight. You know, those big overarching
insights about regulations, about post market
surveillance, and how all of that connects with
the always evolving challenges of making sure
drug quality is top notch. Exactly. Think of
it as like, you know, connecting the dots. We
want to look at how the regulations themselves,
the monitoring systems, all of that, how it's
designed to tackle those real world issues of
ensuring that the medicines we all rely on are
both high quality and, of course, safe for everyone
who uses them. Yeah, because at the end of the
day, that's really what it's all about. Absolutely.
And to do that, we'll be drawing on conversations,
examples, you know, all that good stuff from
across Season 8. We'll touch on some of the major
guidelines like the Code of Federal Regulations,
Title 21, we've mentioned that a few times. CFR.
Right, the CFR. And we'll also be revisiting
those key principles from all those important...
industry handbooks, the ones about good manufacturing
practices, GMP. Oh yeah, GMP. We've talked a
lot about GMP. Yeah, for sure. And the whole
process of validation, and then the complexities
of drug development itself. So it's a lot of
ground to cover, but it'll help paint that bigger
picture. OK, so for you listening, think of this
deep dive as like a fast track to understanding
the big themes, you know, those major takeaways
about how drugs are regulated, what happens after
they're approved. And this is what we call postmarket
safety and how all of this ties into the constant
work of maintaining and improving drug quality
in the pharmaceutical industry. That's a good
way to put it. So let's jump right in. I'm really
curious about this whole idea of monitoring drugs
after they reach patients. How does that actually
connect with all the efforts to achieve those
high quality standards we aim for right from
the start? I'm talking about during the development,
during manufacturing, all of that. That's a really
important point. You see, post -market surveillance,
it's not just an afterthought. It actually creates
this vital feedback loop. It's mandated by regulatory
bodies. And it's essential for catching quality
issues that might have slipped through the cracks,
even after all that rigorous pre -market testing.
We've touched on this throughout the season in
various ways. But a prime example is the whole
system of adverse event reporting. So doctors.
patients, they report any negative effects that
pop up that weren't really expected, that weren't
really predicted. Makes sense, catching those
unexpected problems. Exactly, and you know, if
you remember from our D5 in Season 3 on drug
interactions, and this is pretty striking, the
FDA's own reports. showed this huge jump in post
-marketing adverse events between 1995 and 2004
that really highlights that just because a drug
gets approved, it doesn't mean we fully understand
everything about how it'll behave out there in
the real world. So it's like, the learning process
continues even after a drug is on the market,
and the FDA plays a critical role in watching
over all of that. Right, absolutely. They're
the watchdogs. Right. And like we talked about
in season five, the company that makes the drug,
the sponsor, they have this clear responsibility
to report any safety concerns. So they're part
of that feedback loop too. For sure. They're
on the front lines. OK, so we've got the surveillance
system, we've got the sponsors, and we've got
the FDA all working to ensure things are running
smoothly. But how does all of this tie back into
good manufacturing practices, GMP, those like
ground rules for making drugs that we've explored
quite a bit across several seasons. I'm thinking
specifically about things like the ICHQ7 principles
we looked at in season six, right? That was all
about the guidelines for GMP. And then there's
the specifics of rework procedures from season
five and preventing contamination, which we covered
in season eight, actually, referencing the CFR.
Okay. So if we take a step back and connect all
of these pieces, what we see is that Sticking
to those strict quality standards throughout
the entire manufacturing process, that's like
the most fundamental step towards ensuring safety
once the drug is actually being used by patients.
Think of it this way. If there are inconsistencies
in how the drug is made, right? Maybe from batch
to batch, there's some variation. Or if any unwanted
substances find their way into the product, that's
what we mean by contamination. Or let's say batches
that don't meet the exact specifications need
to be fixed or adjusted. That's what we call
rework. Now, if any of these processes aren't
handled super carefully, documented meticulously,
all of which are key points in those GMP guidelines
like ICHQ -7, then what happens is that those
initial quality problems can directly snowball
into safety issues for patients down the road.
So it's like a ripple effect. The quality built
into the product from the very start, that's
what really minimizes the chances of running
into problems that the post -market surveillance
is then trying to catch. Exactly. It's about
prevention as much as it is about detection.
Okay, so it's all connected. The regulations,
the surveillance, they're like a safety net,
right? Catching anything related to quality or
safety that maybe wasn't so obvious during the
development and production phase. That's a great
analogy. A safety net. Now, I know you mentioned
earlier some cases from season three where certain
drugs were actually taken off the market because
of metabolic drug. drug interactions. Can you
remind us about some of those specific drugs?
And more importantly, what did we learn about
this connection between quality and safety from
those situations? Yeah, absolutely. So those
withdrawals, they provide some pretty stark lessons.
We're talking about drugs like terfenidine, estemazole,
sysapride, meberfridyl, cerevastatin. Those were
all pulled from the U .S. market between 1997
and 2002. Wow, a whole bunch of them. Yeah, and
the thing is, many of these withdrawals were
directly related to how these drugs were metabolized
in the body, you know, how they're broken down,
and how that process could be significantly altered
by other drugs a patient might be taking at the
same time. So, for instance, terfenidine, astamazole,
and sisipride, they were all found to be metabolized
by a very specific enzyme in the liver. It's
called CYP3A4. It's kind of a big deal because
it plays a key role in how our bodies process
many, many medications. Now, when another drug
came along and inhibited or blocked this enzyme,
it actually caused the levels of those first
drugs, the triphenidine and the estemazole, to
increase in the patient's system, and that led
to some pretty serious problems. Oh, I see. So
it's like a cascade of events. One drug messes
with the enzyme, the other drug builds up, and
then things go wrong. Yeah, precisely. And in
some cases, those problems were pretty severe,
potentially fatal heart rhythm abnormalities,
specifically what's called QT prolongation, or
even more serious arrhythmias in some individuals.
So it wasn't necessarily that the drug itself
was inherently flawed in terms of its quality
when it was first manufactured, but rather it
was this unforeseen interaction with other medications
that revealed a significant safety risk once
it was already being used by lots and lots of
people. It really highlights how incredibly complex
the human body is and how difficult it can be
to predict every single interaction that might
happen during the drug development process. You
hit the nail on the head. It's like trying to
solve a giant puzzle. But you don't have all
the pieces. And sometimes you don't even know
what the picture is supposed to look like. Exactly.
In these cases, those withdrawals, they really
drove home the importance of doing very thorough
pre -market studies specifically focused on those
potential drug interactions. It's about understanding
how a new drug might affect those key metabolic
enzymes in the liver, either by blocking them,
like we saw with those examples, or even by making
them work faster, which can also have implications.
So it's all about building that essential knowledge
base before the drug becomes widely available
to patients. So it's all about anticipating those
potential problems as much as possible. Proactive
rather than reactive. Now, you also mentioned
earlier the potential impact of variability in
the quality of the API, the active pharmaceutical
ingredient that's like the heart of the drug,
the part that actually has the intended effect.
We touched on this back in season two when we
were talking about, you know, the early stages
of drug development and the whole issue of how
well a tablet dissolves. Can you remind us how
the quality of the API can actually affect the
safety? of a drug once it's out there being used?
Yeah, absolutely. This really gets to the heart
of consistency. As we discussed back then, if
the quality of the API varies too much from one
batch to another, it can actually cause noticeable
differences in how the drug behaves once it's
inside the body. We're talking about its pharmacokinetics,
how the body absorbs it, distributes it, metabolizes
it, and excretes it in its pharmacodynamics,
which is all about how the drug interacts with
the body and produces its effects. For example,
if one batch of API dissolves at a slightly different
rate than another batch, it can actually result
in unpredictable absorption into the bloodstream.
And that can have a real impact on both how effective
the drug is and how safe it is for patients.
So those early dissolution measurements we talked
about, those are really crucial for catching
those potential issues that originate right there
with the API. So it's like ensuring that the
foundation is solid. If you start with inconsistencies
in the raw material, it can have these knock
-on effects down the line. Exactly. It's like
building a house on shaky ground. Now, shifting
gears a bit, I remember we talked quite a bit
about regulatory concerns surrounding something
called QT prolongation. I know we mentioned Turfinidine
in that context, and we also revisited this issue
in season six. Can you remind us about the significance
of QT prolongation and why it's such a focus
for regulators? Yeah, so QT prolongation, it's
basically an abnormality in the heart's electrical
activity. And the thing is, it can sometimes
live into a very dangerous, even fatal heart
rhythm problem called torsades to points, or
TDP for short. And the case of turfenidine, which
we've talked about, really brought this risk
into sharp focus. As we explored in our season
three deep dive on safety pharmacology, and again
in our discussion of those cardiovascular safety
studies in season six, there are now very specific
non -clinical testing strategies that are outlined
in the International Council for Harmonization's
guideline, S7B. or ICHS7B for short. A lot of
acronyms. I know, right? It's the language of
the industry. But the key takeaway here is that
this guideline requires some very rigorous testing,
both in the lab and in living organisms, to really
investigate a drug's potential to interfere with
the heart's electrical signals and therefore
potentially cause this arrhythmia risk. So this
preclinical evaluation, it's a crucial step in
protecting patients after the drug is approved
because it allows us to identify and hopefully
mitigate this very specific safety concern pretty
early on in the development process. So it's
another example of how a post -market safety
issue with one particular drug can lead to significant
changes and much stricter testing requirements
for all future drug development. It's like learning
from those past experiences and making sure we're
doing everything we can to prevent similar problems
in the future. Absolutely. It's about continuous
improvement and learning from our mistakes. Now,
I know we also talked about this concept of reworking
batches in season five. It might sound kind of
strange, but under certain conditions, it's actually
allowed. Can you walk us through how this practice
relates to maintaining quality and ensuring safety
once a drug is already out there? Yeah, so reworking
batches, it basically means taking a batch of
the drug product that doesn't quite meet those
required specifications and reprocessing it in
some way to try to bring it up to standard. Now,
it's important to emphasize that this is only
permitted under very specific conditions, and
there's a lot of oversight involved. It's not
just a matter of, you know, sweeping a problem
under the rug. As we discussed, you absolutely
have to do a thorough investigation into why
that batch didn't meet those specifications in
the first place. You have to figure out what
went wrong. And then you have to very carefully
evaluate all the potential risks associated with
actually doing the rework procedure. And the
procedure itself, that has to be super clearly
defined, and it needs to be formally approved
by the quality control unit. So there's a whole
chain of command involved. Lots of checks and
balances. For sure. But most importantly, It
has to be scientifically demonstrated, often
through additional testing, including stability
studies, that the reworked product is actually
equivalent in quality to a batch that was produced
using the original flawless process. It has to
meet all those predefined specifications. So
you're not just trying to fix it. You're trying
to prove that the fix doesn't introduce any new
problems. So it's all about ensuring that the
final quality and therefore the safety profile
of the drug is not compromised in any way, even
if a batch needed some correction along the way.
Exactly. And another really crucial part of this
is that meticulous records of the entire rework
process, every single step, they're absolutely
mandatory. That's all about ensuring complete
traceability and accountability. You need to
know exactly what was done, why it was done,
and what the results were. Okay, so it's definitely
not just about fixing a mistake and moving on.
It's about providing clear, documented proof
that the fix didn't introduce any new quality
or safety concerns. Absolutely. Transparency
is key. Now, let's switch gears a little bit
and talk about some of the big picture lessons
we've learned from those significant shifts that
have happened within the pharmaceutical industry
over the years. I remember we talked in season
three about the increased emphasis on predicting
how a drug will behave in the body. It's pharmacokinetics,
even in those early preclinical stages of development.
How has this increased focus actually impacted
drug safety in the long run? That's a great question.
And, you know, what's really striking is how
the main reasons for clinical trials failing
have actually changed over time. If you go back
to the late 1980s, early 1990s. Poor pharmacokinetic
properties were a huge problem. That basically
means the drug wasn't being absorbed well, or
it was being metabolized too quickly, things
like that. And that was a major reason why drugs
weren't making it through clinical testing. But
thanks to huge advancements in developing those
preclinical tools and techniques, the ones that
allow us to predict how a drug will behave in
the human body, how it's absorbed, distributed,
metabolized, and excreted, we've seen a remarkable
improvement in this area. Now, of course, lack
of efficacy, unexpected safety issues, those
are still major reasons why trials fail. But
the fact that we're so much better now at optimizing
those pharmacokinetic profiles early on in the
preclinical phase means that many of the drugs
that do enter clinical trials actually have a
much stronger foundation for both working effectively
and being safe once they eventually reach the
market. So it's like we're weeding out some of
the problematic candidates earlier on in the
process. Exactly. And having a good pharmacokinetic
profile, it's really, in many ways, a prerequisite
for achieving a good safety profile later down
the road. It's all connected. OK. So understanding
how the body handles the drug right from the
start can prevent a lot of potential problems
down the line, especially when it comes to safety.
And I know we also discussed the increasingly
vital role of those advanced analytical tools
in ensuring drug quality, especially in seasons
two and six. How have these technological leaps
actually contributed to making those marketed
products safer for patients? The progress in
analytical techniques, it's been mind blowing,
really. We have tools now that can detect and
accurately measure even the tiniest amounts of
impurities in both drug substances and drug products,
and we could do it with incredible precision.
And as we discussed when we were talking about
nuclear magnetic resonance or NMR and impurity
analysis back in seasons two and six, regulatory
authorities today, they expect a much, much more
comprehensive understanding of a drug substance's
impurity profile than they did in the past. It's
like the bar has been raised significantly. So
it's all about knowing exactly what's in that
drug substance. Exactly. And alongside those
advancements in analytical techniques, we've
also seen huge improvements in the purification
processes that manufacturers use. So now they're
able to produce these incredibly pure bulk drug
substances. And when you combine that more thorough
understanding of potential impurities with the
use of these much purer starting materials, it
directly translates to safer products on the
market. It significantly reduces the risk of
those unexpected side effects that could be caused
by unknown or unquantified substances. So it's
like we're refining the process at every stage.
Exactly. Now, one last area I want to touch on
is the evolving role of artificial intelligence
in health care. We talked about this a bit in
our deep dives in seasons two and three. What
are some of the unique challenges that AI brings
to the table, especially for post market surveillance?
And what are some of the regulatory considerations
when we're talking about AI based medical devices
and interventions? Oh, this is a fascinating
area and it's changing so rapidly as AI becomes
more and more integrated into different aspects
of health care, whether it's those sophisticated
diagnostic tools. of those super advanced surgical
robots, it brings this whole new set of challenges
for post -market surveillance. And some of the
key concerns revolve around the quality of the
data that these AI systems are trained on. If
the data is biased or incomplete, the AI's output
will be flawed. Then there's the potential for
inherent biases within the algorithms themselves.
And then, of course, there's the whole issue
of ensuring the ongoing safety and security of
these AI -driven systems as they're being used
in real -world clinical settings. We don't want
them making decisions that could harm patients.
It's a lot to consider. It really is. Yeah. And
as we've talked about before, sometimes the proprietary
nature of some AI algorithms and just their sheer
complexity can make it really difficult to fully
understand exactly how they're arriving at their
decisions. It's like a black box. So regulatory
bodies around the world are working hard to adapt
existing regulatory frameworks and develop new
approaches to really address these unique challenges
posed by AI. And some of the big areas of focus
are things like data governance, algorithmic
transparency, and continuous monitoring of how
those AI systems are performing out there in
the real world. We need to make sure they're
doing what they're supposed to be doing. It definitely
sounds like a whole new frontier in the ongoing
quest to ensure the safety and effectiveness
of medical interventions. It's a brave new world
out there. So looking ahead, what are some of
those emerging analytical approaches that you
think are going to be especially influential
in shaping drug safety, regulatory compliance,
and those global regulatory strategies in the
years to come? Ooh, there are some really cool
things on the horizon. One of the key approaches
is process analytical technology, or PT, which
we introduced back in season seven. And what
PT does is it allows for real -time monitoring
of those critical quality attributes during the
actual manufacturing process. So instead of just
testing the final product, you're constantly
checking things along the way, making sure everything's
on track. So it's like building quality control
right into the manufacturing process itself.
Exactly. It's about proactive monitoring. continuous
adjustment. And by using various analytical tools
to measure those key quality parameters throughout
the whole production run, PT can really help
to ensure consistent product quality and minimize
the risk of those post -market issues that we've
been talking about. It's all about keeping the
whole process running smoothly within that established
design space as outlined in the International
Council for Harmonization's Guideline Q8, or
ICH Q8 for short. Another acronym. I know, I
know. But the takeaway is that it's about building
quality in from the ground up, not just checking
it at the very end. It sounds like a much more
robust approach. Definitely. And we're also seeing
incredible advancements and broader applications
of those really sophisticated analytical techniques
like liquid chromatography, atmospheric pressure,
chemical ionization mass spectrometry, or LC
-ARC -MS, and atmospheric pressure photoionization
mass spectrometry, or APP -IMS. We talked about
both of those. back in seasons two and six. And
these are just incredibly powerful tools. They
allow us to get this super detailed, comprehensive
characterization of drug substances and any impurities
they might contain. And that deeper understanding
really helps us to create much more accurate
safety profiles and ensures that we're meeting
those increasingly stringent regulatory expectations
around the world. So it's like having a super
powered magnifying glass to examine every nook
and cranny of a drug substance. That's a good
analogy. And then on top of all of that, we're
seeing the fundamental principles of quality
by design or QBD really influencing the way clinical
trials themselves are conducted. We went deep
into QBD back in season seven. Yeah, QBD is all
about building quality into the design from the
get -go. Exactly. And now we're seeing those
principles being applied to the clinical trial
process itself. So researchers are using these
really robust statistical metals within a QBD
framework to optimize the design of clinical
trials, to better control variability in the
data they're collecting, and ultimately to just
enhance the reliability and the interpretability
of those trial results. So it's a much more data
-driven, proactive approach that leads to a more
thorough and trustworthy understanding of a drug's
safety and efficacy profile. And that knowledge
is crucial not just before the drug gets approved,
but it also provides a much stronger foundation
for all that ongoing post -market monitoring
and those risk management strategies that we've
been talking about. So it's like taking a holistic
view, applying those quality principles across
the entire life cycle of a drug from its initial
design all the way through to how it's used in
patients. Exactly. It's a life cycle approach
to quality. And finally, I know we've had some
interesting conversations about the emergence
of continuous manufacturing in the pharmaceutical
industry, especially back in our deep dive in
season six. Can you talk a bit about how this
shift in manufacturing technology might impact
drug quality and safety down the road? Oh, continuous
manufacturing. It's got the potential to be a
real game changer for the industry. The whole
different way of thinking about how we make drugs.
So instead of using those traditional batch -based
processes, where you make a batch, then test
it, then move on to the next batch, continuous
manufacturing uses these integrated continuous
flow systems. And what that does is it gives
manufacturers much, much greater control over
the entire production process. And potentially,
it allows them to achieve those consistently
high levels of product quality that we're always
striving for. And the really interesting thing
is that regulatory bodies, including the FDA,
they're really taking notice. They're actually
encouraging the adoption of these continuous
manufacturing technologies, as you can see reflected
in guidelines like ICH Q13 and various statements
from the agency itself. And that's because this
enhanced process control and the reduction in
those manual interventions that you typically
see in batch processes, they can really lead
to the production of much more consistent and
ultimately safer drug products for patients.
Wow, it sounds like a really exciting development,
and it'll be fascinating to see how it all unfolds
in the coming years. It's definitely one to watch.
So to bring it all together, this has been a
really fascinating overview, kind of like weaving
together all those key threads from our discussions
throughout the entire season. It seems like the
overarching themes revolve around this essential
interplay between establishing those rock -solid
quality practices from the very beginning, right
from the design and manufacturing stages, and
having those robust, responsive post -market
surveillance systems in place to catch any unexpected
hiccups and really drive continuous improvement
in both quality and safety. It's a two -pronged
approach. Absolutely. You need both sides of
the coin. And all the advancements we've talked
about. those increasingly sophisticated analytical
techniques and those ever evolving, more stringent
regulatory approaches. It's all ultimately aimed
at making sure that medicines are as safe and
reliable as they can possibly be for patients
all around the world. It's a global effort. And
that brings us to our final thought for all of
you listening out there. Given how complex pharmaceutical
development is becoming and that constant push
for innovation in medicine, how do you think
future advancements in predictive analytics and
the way we're integrating real -world data, how
might those things further transform our approach
to post -market safety surveillance? How might
they help us to become even more proactive in
identifying and tackling those emerging quality
challenges in the years ahead? It's a big question,
but it's one worth pondering. exploring any of
these topics further, we encourage you to revisit
any of our Season 8 deep dives that particularly
piqued your interest. And of course, those regulatory
guidelines we've mentioned, like the CFR and
the ICH documents, those are always great resources
if you want to really delve into the nitty -gritty
details. Absolutely. Knowledge is power. Well,
that brings us to the end of our Season 8 recap
deep dive. Thanks for joining us on this journey.
It's been a pleasure. And we'll catch you next
time on the deep dive.